Difference between revisions of "Okroj M, et al. Cancer Treat. Rev. (2013) cited as Ref 717 in DOI: 10.1038/s41392-020-0110-5 (Q9980)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 39, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 632-639, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English) | ||
| Property / title: Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 632-639 | ||
| Property / Page(s): 632-639 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:50, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Okroj M, et al. Cancer Treat. Rev. (2013) cited as Ref 717 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Okroj M
0 references
Osterborg A
0 references
Blom AM
0 references
2013
0 references
Cancer Treat. Rev.
0 references
39
0 references
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English)
0 references
632-639
0 references
